Zobrazeno 1 - 10
of 20
pro vyhledávání: '"W J, Tremaine"'
Autor:
W J, Tremaine, W J, Sandborn, E V, Loftus, M L, Kenan, T M, Petterson, A R, Zinsmeister, M D, Silverstein
Publikováno v:
American Journal of Gastroenterology. 96:2401-2406
Practice guidelines should improve care, but they are not routinely followed, in part because of lack of proven benefit. We evaluated the effect of introducing guidelines for inflammatory bowel disease (IBD) on practice variation and the IBD Quality
Autor:
W J, Tremaine
Publikováno v:
Inflammatory bowel diseases. 3(4)
Autor:
W J Tremaine
Publikováno v:
Current Opinion in Gastroenterology. 6:45-49
Autor:
W J, Tremaine, L J, Timmons, E V, Loftus, D S, Pardi, W J, Sandborn, W S, Harmsen, P, Thapa, A R, Zinsmeister
Publikováno v:
Alimentary pharmacologytherapeutics. 25(12)
There is conflicting data regarding the response to medical and surgical therapy for inflammatory bowel disease with respect to age at disease onset.To determine if the age at onset of Crohn's disease and ulcerative colitis is a risk factor for surge
Autor:
W J, Tremaine
Publikováno v:
Alimentary pharmacologytherapeutics. 25(1)
The term indeterminate colitis is imprecise and without a generally accepted definition. Nevertheless, it is a term that is commonly used by gastroenterologists, pathologists and surgeons.To offer an opinion supported by published data, about the app
Autor:
W J Tremaine
Publikováno v:
The Netherlands Journal of Medicine. 50:S12-S14
Refractory inflammatory bowel disease (IBD) can be defined as persistent acute symptomatic disease despite anti-inflammatory therapy or as chronically active disease requiring continuous treatment for relief of symptoms. Treatment options include aza
Autor:
W J, Tremaine, A, Brzezinski, J A, Katz, D C, Wolf, T J, Fleming, J, Mordenti, L C, Strenkoski-Nix, M C, Kurth
Publikováno v:
Alimentary pharmacologytherapeutics. 16(3)
Mast cells isolated from the colonic mucosa in active ulcerative colitis appear to be partially degranulated, suggesting the release of tryptase.To investigate the safety and activity of APC 2059, a highly specific tryptase inhibitor, in the treatmen
Publikováno v:
Inflammatory bowel diseases. 6(4)
This study reports the clinical outcome, toxicity, and methotrexate pharmacokinetics after the addition of low-dose cyclosporine to methotrexate in patients with ulcerative colitis or Crohn's disease.Three patients with steroid-refractory ulcerative
Publikováno v:
Mayo Clinic proceedings. 75(5)
To evaluate a possible etiologic role of alpha1-antitrypsin deficiency (alpha1AD), most frequently caused by a Z allele mutation, in ulcerative colitis (UC) and Crohn disease (CD).This retrospective study included 10 patients diagnosed with and/or tr
Autor:
L J, Egan, W J, Sandborn, W J, Tremaine, J A, Leighton, D C, Mays, M G, Pike, A R, Zinsmeister, J J, Lipsky
Publikováno v:
Alimentary pharmacologytherapeutics. 13(12)
The optimum initial dose of methotrexate for steroid-requiring inflammatory bowel disease is not known.To compare directly the efficacy and toxicity of methotrexate 15 and 25 mg/week, and to explore the value of methotrexate blood levels as predictor